Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy.
OBJECTIVE
The aim of this study was to describe a case of angiographically documented foveal avascular zone (FAZ) enlargement after intravitreal bevacizumab following vitrectomy and intravitreal bevacizumab treatment of a diabetic patient.


METHODS
This study was done as a case report.


RESULTS
A 40-year-old diabetic man was treated with a pars plana vitrectomy and intravitreal bevacizumab for a nonclearing vitreous hemorrhage. Despite successful surgery, the postoperative best-corrected visual acuity was not improved. FAZ area had increased from 1.48 mm(2) preoperatively to 1.96 mm(2) postoperatively (24.5% increase).


CONCLUSIONS
Although intravitreal bevacizumab is an effective modality for diabetic retinopathy, it may deteriorate pre-existing retinal ischemia.
Lee
Sung Jun
SJ
The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
Koh
Hyoung Jun
HJ
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000601:surgery; D005451:Fluorescein Angiography; D005584:Fovea Centralis / Q000098:blood supply / Q000473:pathology*; D006801:Humans; D006984:Hypertrophy; D007267:Injections; D008297:Male; D014821:Vitrectomy; D014822:Vitreous Body; D014823:Vitreous Hemorrhage / Q000188:drug therapy* / Q000601:surgery
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab